Investigational drug · Phase 3
luvometinib
Also called: FCN-159
Not approved by FDA. In 4 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Non-small Cell Lung Caner, KRAS-mutated, Metastasis.
Phase 3Last checked: Nov 19, 2026Latest source record: Sep 2, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
4
4 still active
All registered trials
8
Any phase or sponsor naming "luvometinib"
First trial start
2023
Sep 28, 2023
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "luvometinib", any sponsor or status.
Conditions studied
As listed on its trial records.
- Non-small Cell Lung Caner
- KRAS-mutated
- Metastasis
- Previous Treamted
- Neurofibromatosis 1
- Plexiform Neurofibroma
- NF1
- Low-grade Glioma
- Pediatric Low-grade Gliomas
- pLGG With BRAF Alteration
Approved drugs for the same conditions: Brain tumors (glioma) · Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "luvometinib" as an intervention, largest first.
- Platform Research for Innovative Medicines in NF2-SWN (PRIME-NF2)Pivotal-lookingNot yet recruiting
Beijing Tiantan HospitalAcademic, hospital or other
NCT07713745 · 200 participants (planned) · Start Jul 18, 2026 · Primary completion Jun 1, 2036
Drug: Selumetinib 25mg/m2; Luvometinib and 1 more · For: Neurofibromatosis Type 2; Vestibular Schwannoma; Non-vestibular Schwannoma and 4 more
Sites: Beijing, China; Changchun, China; Shanghai, China · 5 sites in all
- Modified LCH-III Regimen With or Without Luvometinib for Multisystem Pediatric Langerhans Cell HistiocytosisPivotal-lookingRecruiting
West China Second University HospitalAcademic, hospital or other
NCT07431060 · 120 participants (planned) · Start Feb 13, 2026 · Primary completion Dec 31, 2030
Drug: Prednisone; Vincristine and 2 more · For: Langerhans Cell Histiocytosis (LCH)
Sites: Chengdu, China; Guiyang, China; Hefei, China · 11 sites in all
- FCN-159 Monotherapy Versus Chemotherapy by Investigator's Choice in Pediatric Low-grade Glioma Patients With BRAF AlterationPivotal-lookingNot yet recruiting
Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.Industry
NCT07004075 · 102 participants (planned) · Start Jun 30, 2025 · Primary completion Apr 30, 2027
Drug: Luvometinib; Chemotherapeutic Agent COG-V/C Carboplatin + Vindesine, Carboplatin, Temozolomide · For: Low-grade Glioma; Pediatric Low-grade Gliomas; pLGG With BRAF Alteration
Sites: Beijing, China
- Follow-up Study to Evaluate the Safety and Efficacy of FCN-159 in Pediatric Participants With Neurofibromatosis Type 1Not yet recruiting
Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.Industry
NCT07024394 · 65 participants (planned) · Start Jun 12, 2025 · Primary completion Sep 23, 2029
Drug: Luvometinib Tablets · For: Neurofibromatosis 1; Plexiform Neurofibroma; NF1
Sites: Shanghai, China
West China Second University HospitalAcademic, hospital or other
NCT07371182 · 62 participants (planned) · Start Jun 19, 2026 · Primary completion Dec 31, 2030
Drug: Luvometinib · For: Langerhans Cell Histiocytosis (LCH)
Sites: Hefei, China; Nanning, China; Guiyang, China · 11 sites in all
Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.Industry
NCT07562581 · 48 participants (planned) · Start Jun 15, 2026 · Primary completion Jun 2029
Drug: luvometinib + anlotinib; luvometinib + anlotinib · For: Non-small Cell Lung Caner; KRAS-mutated; Metastasis and 1 more
Sites: Shanghai, China
- Response-adapted Luvometinib With or Without Cytarabine in Langerhans Cell HistiocytosisNot yet recruiting
Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong UniversityAcademic, hospital or other
NCT07728201 · 30 participants (planned) · Start Jun 30, 2026 · Primary completion Jul 31, 2028
Drug: Luvometinib; Luvometinib, Cytarabine. · For: Langerhans Cell Histiocytosis
Sites: Shanghai, China
- Luvometinib in Combination With Serplulimab for NF2-Related TumorsNot yet recruiting
Beijing Tiantan HospitalAcademic, hospital or other
NCT07708285 · 30 participants (planned) · Start Jul 31, 2026 · Primary completion Dec 31, 2028
Drug: Luvometinib; Serplulimab · For: NF2-related Schwannomatosis; NF2; Neurofibromatosis Type 2 and 2 more
Sites: Beijing, China; Changchun, China; Shanghai, China · 5 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- From MEK inhibition to rational combination strategies for NF1-associated plexiform neurofibromas.
Diao S, Qin H, Kong J, et al. · Front Oncol 2026
- Targeted pharmacotherapy of NF1-associated plexiform neurofibromas: current evidence and future perspectives.
Fertitta L, Pasmant E · Expert Opin Pharmacother 2026
- Luvometinib as a salvage therapy for a patient with PTPN11-positive juvenile myelomonocytic leukemia.
Cheng J, Wei N, Lu Y, et al. · Leuk Res 2026
- A Phase 2 Study of the MEK1/2 Inhibitor Luvometinib in Patients with Extracranial Arteriovenous Malformations.
Hua C, Wu Z, Wang X, et al. · Clin Cancer Res 2026
- Phase 1 Study of Luvometinib Use in Pediatric Patients with Neurofibromatosis Type 1-Related Unresectable Plexiform Neurofibromas.
Hu X, Wu Z, Wang J, et al. · Target Oncol 2025
- Luvometinib in patients with Langerhans cell histiocytosis, Erdheim-Chester disease, and other histiocytic neoplasms: a single-arm, multicentre, phase 2 study.
Cao XX, Zhu Q, Cai Z, et al. · EClinicalMedicine 2025
Also in development for Non-small Cell Lung Caner
- Anlotinib hydrochlorideAL3818, CatequentenibPhase 312 trials
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Alveolar Soft Part Sarcoma, Metastatic Colorectal Cancer, Endometrial Neoplasms
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.